Regeneron beats quarterly profit estimates on Dupixent strength [Yahoo! Finance Canada]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance Canada
Dupixent, which Regeneron co-develops with French drugmaker Sanofi, has ?become an increasingly important growth driver as sales of its eye disease drug, Eylea, faces ?pressure from cheaper versions and rival treatments such as Roche's Vabysmo. Investors are also focused on how Regeneron and Sanofi will mitigate a sales hit for Dupixent, which will lose key patents beginning in 2031. Sanofi Chief Financial Officer François-Xavier ?Roger said on Thursday the ?company would not be able to offset the loss of sales once Dupixent, its largest revenue driver, comes off ?patent. Quarterly Dupixent sales recorded by Sanofi rose 34% to $4.9 billion, in line with analysts' expectations. Total Eylea sales for the quarter fell 28% to $1.1 billion, missing estimates of $1.25 billion, ?according to data compiled by LSEG. Sales of Regeneron's cancer treatment, Libtayo, ?were at $425 million, compared with the estimate of $375.68 million. Regeneron had been facing several regulatory setb
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]Yahoo! Finance
- GSK Advances Respiratory And Vaccine Growth With Key RSV And Asthma Moves [Yahoo! Finance]Yahoo! Finance
- Latent TB Diagnostics Research Report 2026: Global Market Analysis and Forecasts 2025-2029 by Assay, Risk Factor, and Lab/Place with Executive and Consultant Guides [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website